Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Part 1: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Arm 4)

  Measured over: Up to approximately 97 weeks

• Part 1: Number of Participants With Any TEAEs and SAEs (Arm 5)

  Measured over: Up to approximately 107 weeks

• Part 1: Number of Participants With Dose Limiting Toxicity (DLT) (Arm 4 and Arm 5)

  Measured over: Up to 21 days

• Part 1: Number of Participants Requiring Dose Modifications (Arm 4)

  Measured over: Up to approximately 97 weeks

• Part 1: Number of Participants Requiring Dose Modifications (Arm 5)

  Measured over: Up to approximately 107 weeks

• Part 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (Arm 4)

  Measured over: Up to approximately 97 weeks

• Part 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (Arm 5)

  Measured over: Up to approximately 107 weeks

• Part 1: Number of Participants With Worst-case Post Baseline Increase From Baseline in Vital Signs (Arm 4)

  Measured over: Up to approximately 97 weeks

• Part 1: Number of Participants With Worst-case Post Baseline Increase From Baseline in Vital Signs (Arm 5)

  Measured over: Up to approximately 107 weeks

• Part 1: Number of Participants Who Received Concomitant Medications (Arm 4)

  Measured over: Up to approximately 97 weeks

• Part 1: Number of Participants Who Received Concomitant Medications (Arm 5)

  Measured over: Up to approximately 107 weeks

• Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline Electrocardiogram (ECG) Findings (Arm 4)

  Measured over: Up to approximately 97 weeks

• Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline ECG Findings (Arm 5)

  Measured over: Up to approximately 107 weeks

• Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in QTcF Interval (Arm 4)

  Measured over: Up to approximately 97 weeks

• Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in QTcF Interval (Arm 5)

  Measured over: Up to approximately 107 weeks

• Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in Left Ventricular Ejection Fraction (LVEF) (Arm 4)

  Measured over: Up to approximately 97 weeks

• Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in Left Ventricular Ejection Fraction (LVEF) (Arm 5)

  Measured over: Up to approximately 107 weeks

• Part 1: Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 4)

  Measured over: Up to approximately 97 weeks

• Part 1: Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 5)

  Measured over: Up to approximately 107 weeks

• Part 1: Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 4)

  Measured over: Up to approximately 97 weeks

• Part 1: Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 5)

  Measured over: Up to approximately 107 weeks

• Part 1: Number of Participants With Worst Case Change Post-baseline in Clinical Chemistry Parameters (Arm 4)

  Measured over: Up to approximately 97 weeks

• Part 1: Number of Participants With Worst Case Change Post-baseline in Clinical Chemistry Parameters (Arm 5)

  Measured over: Up to approximately 107 weeks

• Part 1: Number of Participants With Worst-Case Urinalysis Results Post-Baseline Relative to Baseline (Arm 4)

  Measured over: Up to approximately 97 weeks

• Part 1: Number of Participants With Worst-Case Urinalysis Results Post-Baseline Relative to Baseline (Arm 5)

  Measured over: Up to approximately 107 weeks

• Part 2: Overall Survival (OS)

  Measured over: Up to approximately 107 weeks

Changes Tremor has spotted